Be sure to catch up on the latest happenings in our spring newsletter here! Nancy Farrugia Related postsIntellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) AmyloidosisNovember 18, 2024Amyloid Removal Looks Possible in ATTR Cardiomyopathy Imaging TrialMay 25, 2023Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CMApril 3, 2025 Previous post2026 Winter Newsletter
